But semaglutide works through a single pathway, the GLP-1 receptor, and that single-pathway approach comes with inherent limitations in how much weight it can help someone lose and what metabolic benefits it can deliver beyond appetite suppression
A number of studies have demonstrated sustained weight loss post-medication removal
They are not intended for human consumption, diagnostic, or therapeutic use
Comparison of the Impact of SGLT2-Inhibitors and Exenatide on Body Fat Composition
LSM changes in Appetite VAS and Eating Inventory from baseline with retatrutide were compared to those with placebo and dulaglutide at Weeks 4, 8, 12, 16, 24, and 36, and Weeks 24 and 36, respectively
The gut microbiome, made up of trillions of microorganisms, plays a key role in this process